Drugs / GnRH antagonist
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04043520 | Sep 2019 → Aug 2024 | abdominal obesity-metabolic syndrome | University of Colorado, Denver | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03291821 | Dec 2017 → Dec 2019 | female infertility | IVI Madrid | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00696878 Background | Sep 2006 → Feb 2009 | — | Organon and Co | Completed | No outcome recorded |
| — | NCT03484611 Comparator | Jan 2013 → Apr 2018 | — | Cairo University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GnRH antagonist | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04043520 ↗ |
| Route | Subcutaneous | “GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.” NCT00696878 ↗ |